$13.640
-0.331 (-2.43%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
Predicción y previsión de RNA por análisis de gráficos similares
Alphio's RNA stock price prediction model matches the current Atrium Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $13.64 (+0.03%). The 1-week path is $13.37 (-2.00%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
¿Debería comprar acciones de Atrium Therapeutics Inc?
Avidity Biosciences Inc appears to be a good buy right now due to its current price of $13.64, which is significantly below the analyst price target of $25, suggesting a potential upside of 83.5%. Additionally, the stock has shown a positive 20-day change of +20.18%, indicating a recent upward trend. However, investors should be cautious of the high insider selling activity, which has increased by 200.63% over the last month, indicating potential concerns among insiders.
RNA cerró en $13.64 el Friday, tras bajar -2.43%
Atrium Therapeutics Inc (RNA) last closed at $13.64, losing -2.43%. These facts feed the 1-day and 1-week RNA price prediction above.
Factores de la previsión
Los factores de la previsión de Atrium Therapeutics Inc (RNA) combinan patrones gráficos similares, estacionalidad y medias móviles.
Similar patterns
Bullish
Seasonality
Bullish
SMA 20
Bullish
SMA 200
Bearish
Patrones gráficos similares
Acciones cuya trayectoria reciente más se parece a la de RNA, ordenadas por similitud.
Análisis de estacionalidad de RNA
Historically the probability of a positive August return for RNA is 67.19%. September offers the highest probability of a positive month at 100.00%, while April is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.